# Dermatology Marketing Compliance: Medical, Cosmetic, and Skin Cancer Claims That Draw Enforcement Dermatology practices combine medical dermatology, cosmetic dermatology, and increasingly med-spa-adjacent services. Each creates its own compliance considerations. Here's the full framework. By RegenCompliance Editorial (FDA/FTC compliance desk). Published 2026-01-19. Reading time 9 minutes. Canonical page: https://regencompliance.ai/blog/dermatology-marketing-compliance Dermatology practices typically offer a mix of medical dermatology (acne, psoriasis, eczema, skin cancer screening), cosmetic dermatology (neurotoxins, fillers, lasers, chemical peels), and increasingly retail or private-label skincare. Each category carries different compliance considerations, and the mix makes dermatology marketing one of the more complex healthcare marketing surfaces. This post covers the category-by-category framework. ## Medical dermatology marketing ### Disease-specific treatment claims Non-compliant “Our treatments cure psoriasis, eczema, and acne permanently.” Compliant alternative “Our practice evaluates and treats psoriasis, eczema, and acne with evidence-based medical protocols. Treatment response varies by individual; ongoing management is typical for chronic conditions.” Why: Specific disease cure claims cross FDA disease-claim rules. Medical dermatology practices legitimately treat these conditions - marketing should describe evidence-based treatment without claiming cures. ### Skin cancer screening marketing Skin cancer screening marketing is a specific category where FTC and state AGs have been active. Claims about detection rates, early-detection outcome benefits, and AI-assisted screening should be substantiated and framed carefully under the [FTC Health Products Compliance Guidance](https://www.ftc.gov/business-guidance/resources/health-products-compliance-guidance). Non-compliant “Our advanced AI screening catches 100% of melanomas earlier than any other method.” Compliant alternative “We offer comprehensive skin examinations including the use of [specific technology]. Early detection improves outcomes in many cases; no screening method is perfect.” Why: Absolute detection claims are unsubstantiable. Comparative superiority claims against other methods require head-to-head evidence. ### Prescription dermatology advertising Branded prescription marketing (biologics like Dupixent, Humira; topicals like brand-name retinoids) falls under prescription drug advertising rules. Most dermatology practices don’t directly market these brands but do reference them in treatment discussions. ## Cosmetic dermatology marketing Cosmetic dermatology shares most of the med spa compliance framework: before/after imagery rules, injectable brand-name rules, [FDA-cleared vs FDA-approved device distinctions](https://regencompliance.ai/blog/fda-approved-vs-fda-cleared-aesthetic-devices), and typical-experience disclosure. See our [med spa marketing compliance](https://regencompliance.ai/blog/med-spa-marketing-compliance-risk) post for the detailed framework that applies. ### Specialty-specific considerations - **Board-certified dermatologist marketing.**ABD certification is widely recognized and supportable when accurately stated. - **Cosmetic specialty framing.** Dermatologists legitimately offer cosmetic services within their scope; “cosmetic dermatologist” is defensible with appropriate backing. - **Physician-performed vs delegated procedures.**Clear marketing of who performs what matters both for consumer understanding and for state medical board compliance. ## Retail and private-label skincare Many dermatology practices sell retail skincare or private- label lines. Cosmetic labeling and claim rules apply: ### Cosmetic vs drug boundary The [FDA structure/function claim guidance](https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/structurefunction-claims) describes what claim language keeps a product within cosmetic or supplement scope rather than triggering drug status. Non-compliant “Our private-label cream heals eczema and reduces inflammation.” Compliant alternative “Our private-label moisturizer is formulated to support skin barrier function and hydration.” Why: Disease-treatment claims (heals eczema, reduces inflammation in a disease context) convert cosmetics into drugs. Structure-function and cosmetic-benefit language stays within cosmetic regulatory scope. ### “Medical-grade” and “cosmeceutical” Neither term has specific FDA definition. Using them in marketing creates an implication of regulatory status that doesn’t exist. Specific framing (“professional-strength,” “clinical-grade formulation”) is typically less problematic than implying FDA endorsement. ### Ingredient claims Specific ingredient outcome claims (“retinol reverses aging,” “vitamin C brightens”) need substantiation. Ingredient-level claims can be more substantiable than product-level claims because research on specific ingredients is often robust. ## Teledermatology marketing Teledermatology adds telehealth-specific rules on top of general dermatology compliance: - **State licensure.** Teledermatology to patients requires provider licensure in the patient’s state. - **Examination standards.** Marketing that minimizes clinical evaluation has drawn state board attention. - **Prescribing rules.** Prescription-based teledermatology faces controlled-substance and store-and-forward rules depending on the prescriptions. - **Asynchronous vs synchronous.** Marketing should accurately describe the actual service model. ## Common mistakes specific to dermatology marketing ### Mistake 1: Conflating cosmetic and medical in claims Dermatology practices legitimately offer both but sometimes blur the lines in marketing in ways that create regulatory overlap. Medical and cosmetic framings each have their own compliance considerations, and marketing should respect the boundary. ### Mistake 2: Skin cancer scare-based marketing Scare-marketing around skin cancer (“don’t wait, skin cancer kills”) triggers consumer-protection scrutiny when it’s paired with promotional offers for screening. Informational content about skin cancer is fine; fear-based conversion tactics face additional scrutiny. ### Mistake 3: Private-label supplement line marketing Dermatology practices selling private-label supplement lines for skin, hair, or nail health face DSHEA rules plus FDA drug-claim concerns on disease claims. Supplement marketing alongside clinical services creates documentation and claim challenges. ### Mistake 4: Before/after without medical dermatology context Before/after imagery for medical dermatology (acne, rosacea, psoriasis) often lacks the clinical context and individual- variation framing that medical marketing requires. Treat medical dermatology before/after with the same rigor as cosmetic dermatology before/after - the [before/after photo compliance guide](https://regencompliance.ai/blog/before-after-photos-compliance) applies equally to both. ## Frequently asked questions ### Can I market non-FDA-approved off-label uses? Clinical off-label use is standard practice; marketing specific off-label uses is a regulatory risk. For dermatology, this often involves biologics used for conditions beyond their labeled indications. ### What about cosmetic claim substantiation? Cosmetic claims still need substantiation under FTC rules, though the evidentiary bar is less strict than for drug claims. Specific outcome claims (“reduces wrinkles by X%”) need supporting evidence. ### Does physician endorsement of products create material connection? If the physician has a financial interest in the product, yes - and the relationship should be disclosed in the endorsement. This is common in private-label situations and is sometimes missed in disclosure practice. ### How do I handle prescription-related content? General patient education about conditions and treatment categories is generally lower-risk. Specific prescription-drug promotion by brand name falls under prescription advertising rules with fair-balance requirements. ### What about social media aesthetic content from dermatologists? Dermatologists’ personal and professional social media content discussing their practice is subject to the same rules as the practice’s official marketing. Personal accounts that discuss practice services aren’t exempt. ### Are there derm-specific insurance considerations? Dermatology malpractice insurance may have specific provisions about cosmetic vs medical practice scope. Advertising exposure (FTC claims, private class action) is typically covered differently than malpractice. Review policies specifically. Key Takeaways - Dermatology marketing combines medical, cosmetic, retail skincare, and teledermatology - each with its own compliance framework. - Specific disease cure claims for dermatologic conditions trigger FDA drug-claim rules even though dermatologists legitimately treat these conditions. - 'Medical-grade' and 'cosmeceutical' are not defined regulatory terms - using them implies endorsement that doesn't exist. - Skin cancer screening marketing faces FTC and state AG scrutiny around detection claims and scare-based conversion tactics. - Private-label skincare and supplement lines add DSHEA and cosmetic-drug boundary considerations to core dermatology marketing. --- RegenCompliance is FDA/FTC compliance scanning software for healthcare marketing, operated by Regen Portal LLC. Educational compliance tool, not legal advice. Not affiliated with the FDA or FTC. Contact: support@regencompliance.ai. Full site index for AI agents: https://regencompliance.ai/llms.txt